Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
28. März 2024 16:05 ET
|
Assembly Biosciences, Inc.
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...
Assembly Biosciences Announces Effective Date of Reverse Stock Split
08. Februar 2024 08:00 ET
|
Assembly Biosciences, Inc.
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc....
Assembly Biosciences Provides Anticipated Development Milestones for 2024
04. Januar 2024 08:00 ET
|
Assembly Biosciences, Inc.
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data...
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10. November 2023 16:05 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
10. November 2023 08:00 ET
|
Assembly Biosciences, Inc.
--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10,...
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
08. November 2023 16:05 ET
|
Assembly Biosciences, Inc.
Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical...
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
08. November 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN...
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
11. Oktober 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
02. Oktober 2023 08:00 ET
|
Assembly Biosciences, Inc.
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies...
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
19. September 2023 16:05 ET
|
Assembly Biosciences, Inc.
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...